Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

This study has been completed.
Information provided by:
Santen Pharmaceutical Co., Ltd. Identifier:
First received: September 30, 2009
Last updated: November 21, 2012
Last verified: November 2012
Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Condition Intervention Phase
Persistent Corneal Epithelial Defect
Drug: DE-105 ophthalmic solution
Drug: Placebo ophthalmic solution
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Further study details as provided by Santen Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • Restoration of corneal epithelial defect [ Time Frame: Every week ]

Secondary Outcome Measures:
  • Visual acuity,etc. [ Time Frame: Exit visit,etc. ]

Estimated Enrollment: 45
Study Start Date: September 2009
Arms Assigned Interventions
Experimental: High concentration
DE-105 high concentration
Drug: DE-105 ophthalmic solution
Topical ocular application
Experimental: Low concentration
DE-105 low concentration
Drug: DE-105 ophthalmic solution
Topical ocular application
Placebo Comparator: Placebo
DE-105 placebo
Drug: Placebo ophthalmic solution
Topical ocular application


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has corneal epithelial defect and decreased corneal sensitivity.
  • Has undergone continuous treatment for corneal epithelial defect for 1 week or longer.

Exclusion Criteria:

  • Presence of disease such as active ocular infection, or abnormal lid closure.
  • History or presence of chemical burn, Stevens - Johnson Syndrome, etc.
  • History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00988494

Santen study sites
Osaka, Japan
Sponsors and Collaborators
Santen Pharmaceutical Co., Ltd.
  More Information Identifier: NCT00988494     History of Changes
Other Study ID Numbers: 01050807
Study First Received: September 30, 2009
Last Updated: November 21, 2012

Additional relevant MeSH terms:
Pharmaceutical Solutions
Ophthalmic Solutions processed this record on May 23, 2017